Hardman Johnston Global Advisors LLC lessened its holdings in Qiagen N.V. (NASDAQ:QGEN) by 0.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 3,606,995 shares of the company’s stock after selling 5,484 shares during the period. Qiagen N.V. accounts for approximately 4.8% of Hardman Johnston Global Advisors LLC’s holdings, making the stock its 6th biggest position. Hardman Johnston Global Advisors LLC owned about 1.58% of Qiagen N.V. worth $113,620,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Acrospire Investment Management LLC increased its stake in Qiagen N.V. by 11.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock worth $112,000 after buying an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Qiagen N.V. in the 1st quarter worth $114,000. Quadrant Capital Group LLC increased its stake in Qiagen N.V. by 4.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock worth $183,000 after buying an additional 225 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Qiagen N.V. in the 1st quarter worth $207,000. Finally, Quantitative Systematic Strategies LLC purchased a new stake in Qiagen N.V. in the 2nd quarter worth $211,000. Institutional investors and hedge funds own 60.35% of the company’s stock.
WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.com-unik.info/2017/11/02/qiagen-n-v-qgen-shares-sold-by-hardman-johnston-global-advisors-llc.html.
A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Cowen and Company reiterated a “hold” rating and issued a $33.00 price target on shares of Qiagen N.V. in a research note on Thursday, September 28th. DZ Bank AG reiterated a “neutral” rating on shares of Qiagen N.V. in a research note on Monday, August 28th. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a research note on Thursday, August 17th. Finally, BidaskClub lowered Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Qiagen N.V. presently has a consensus rating of “Hold” and an average price target of $33.28.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
What are top analysts saying about Qiagen N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen N.V. and related companies.